MON-711: The Rare Sugar Allulose Induces Apolipoprotein A1 Gene Expression

Allulose does more than sweeten

Allulose already earns attention for its sugar-like taste. This study gives another reason to watch it. In human liver cells, allulose turns on the gene for apolipoprotein A-I, the main protein in HDL particles. The effect is large: more than two-fold. That raises a new possibility for formulators and buyers. Allulose may help support heart health, not just replace sugar.

Background

HDL is often called the “good” cholesterol carrier. Apo A-I is the key protein that makes HDL work. This paper, available under DOI 10.1210/jendso/bvaa046, uses HepG2 cells, a human liver cell line. The researchers looked at whether allulose could push those cells to make more apo A-I. They found a clear signal.

What the study did

The study team treated HepG2 cells with allulose. They measured apo A-I secretion and mRNA levels. They also probed the gene’s promoter region to understand the mechanism. The response was dose-dependent. At both protein and mRNA levels, apo A-I increased more than two-fold. The gene activation depended on a specific DNA element called the insulin response core element (IRCE). The transcription factor SP1 also mediated the effect. Without those pieces, allulose could not trigger the same response.

Key findings

Measured response	Observed effect
Apo A-I protein secretion	More than two-fold increase, dose-dependent
Apo A-I mRNA	More than two-fold increase, dose-dependent
Gene promoter control	IRCE required
Transcription factor	SP1 mediates the effect
Predicted outcome	Higher HDL may contribute to anti-atherosclerotic activity

The dose-dependent pattern matters. It means the effect tracks with allulose concentration. More allulose, more response. That is exactly the kind of relationship formulators want to see before investing in a functional ingredient.

What it means for manufacturers

This is early-stage evidence, not clinical proof. Still, it shifts the conversation. Allulose may function beyond sweetness. For product developers, that opens a possible heart-health angle in beverages, bars, baked goods, and other applications.

For ingredient buyers, this study is a signal. Ask suppliers for updates on human research. If future trials show that allulose raises HDL in people, the ingredient’s value changes. A sweetener that also supports HDL production would stand out in a crowded market.

Do not build label claims on cell data. Regulatory bodies require human evidence. But you can use this mechanism to guide internal strategy. R&D teams can start exploring allulose in concepts aimed at cardiovascular wellness. Marketing teams can watch for stronger data.

FAQ

What is apo A-I and why does it matter?

Apo A-I is the main protein in HDL particles. HDL helps remove cholesterol from tissues, which is why higher HDL levels are generally associated with lower cardiovascular risk. Allulose appears to increase apo A-I production in liver cells.

Does this prove allulose raises HDL in humans?

No. This study used cultured liver cells. It shows a molecular pathway, not a clinical outcome. Human intervention studies need to confirm whether eating allulose changes apo A-I or HDL levels in the body.

Should I reformulate with allulose now for heart-health positioning?

Not based on this paper alone. But the mechanism gives you a reason to track the science. If the human data follow, early movers will have a head start.

Allulose keeps evolving

This paper adds a credible mechanism to allulose’s story. The dose-dependent, two-fold increase in apo A-I expression is worth attention. The involvement of IRCE and SP1 makes the finding biologically plausible. Now the question is translation. Will allulose do the same in humans? That answer will determine whether this rare sugar becomes a functional heart-health ingredient or remains a very useful sweetener.